Background Medication-related osteonecrosis of the jaw (MRONJ), which was first reported
as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in bisphosphonate users, is a …

Background Antiresorptive agents such as bisphosphonates and denosumab, as well as
angiogenesis inhibitors, may induce medication-related osteonecrosis of the jaw (MRONJ) …

Purpose No consensus has been reached regarding the best treatment option for early-
stage lesions in medication-related osteonecrosis of the jaw (MRONJ). The purpose of the …

Osteoporotic bone regeneration is a challenging process which involves the occurrence of
sophisticated interactions. Although various polymeric scaffolds have been proposed for …

Medication-related osteonecrosis of the jaw (MRONJ) is one of the most interesting diseases
in the field of maxillofacial surgery. In addition to bisphosphonates, the use of antiresorptive …

Bone physiology relies on the delicate balance between resorption and formation of its
tissue. Bone resorption depends on a process called osteoclastogenesis in which bone …

Medication‐related osteonecrosis of the jaw (MRONJ) is a severe side effect of
antiresorptive (bisphosphonates and denosumab) and anti‐angiogenic therapy used in the …

Root amputation, immunosuppressive therapy, mandibular tooth extraction, pre-existing
inflammation, and longer duration of treatment with bone-modifying agents were significantly …

Methods for preventing medication-related osteonecrosis of the jaw (MRONJ) in cancer
patients who have received high-dose bisphosphonate (BP) or denosumab (Dmab) have …

This study evaluated the effects of antimicrobial photodynamic therapy (aPDT) in the
alveolar repair of rats with major risk factors for bisphosphonate-related osteonecrosis of the …